The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 24 of the 40 sources its claims cite were checked for support.
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Open accessAbstract
Background An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R 2 ) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R 2 versus R 2 in participants with relapsed or refractory follicular lymphoma after at least one previous line of chemoimmunotherapy. Methods In this multicountry, open-label, phase 3 trial, participants were randomly allocated (1:1) to fixed-duration epcoritamab plus R 2 or R 2 for up to 12 cycles. Epcoritamab was administered weekly in cycles 1–3 and every 4 weeks in cycles 4–12, lenalidomide once daily during cycles 1–12 (days 1–21), and rituximab weekly during cycle 1 and monthly in cycles 2–5. The dual primary endpoints were overall response rate and progression-free survival by independent review committee. The data reported here are from a planned interim analysis carried out after 78% of progression-free survival events had occurred. This study is registered with ClinicalTrials.gov, NCT05409066, and EudraCT, 2021–000169–34, and is ongoing (closed to recruitment). Findings Out of 668 participants screened for eligibility across 189 academic and non-academic centres in 30 countries across Africa, Asia, Australia, Europe, North America, and South America, a total of 488 participants were randomly allocated, 243 to epcoritamab plus R 2 and 245 to R 2 . The trial met its dual primary endpoints, showing superiority of epcoritamab plus R 2 over R 2 in overall response rate and progression-free survival. With a median follow-up of 14·8 months (IQR 11·4–19·0), overall response rate was 95% (95% CI 92–97) with epcoritamab plus R 2 versus 79% (74–84; p<0·0001) with R 2 . Progression-free survival was longer with epcoritamab plus R 2 versus R 2 (hazard ratio 0·21 [95% CI 0·14–0·31], p<0·0001); estimated 16-month progression-free survival favoured epcoritamab plus R 2 (85·5% vs 40·2%). Grade 3 or higher adverse events were more frequent with epcoritamab plus R 2 (219 [90%] of 243 participants) versus R 2 (161 [68%] of 238 participants). Cytokine release syndrome was low grade with epcoritamab plus R 2 (grade 1 in 28 [21%] participants and grade 2 in seven [5%] participants) and manageable, and all events were resolved. Interpretation Epcoritamab plus R 2 resulted in significantly higher response rate and longer progression-free survival versus R 2 among participants with follicular lymphoma who had received at least one line of therapy. Epcoritamab plus R 2 had more grade 3 or higher adverse events versus R 2 . Adverse events were manageable and consistent with the established safety profiles of the individual components, with no new safety findings identified. These findings position epcoritamab plus R 2 as a new standard of care for second-line or subsequent treatment of follicular lymphoma. Funding AbbVie and Genmab.
Overview
CoChat Summary
TL;DR
In EPCORE FL-1, fixed-duration epcoritamab plus lenalidomide and rituximab significantly improved overall response rate and progression-free survival versus R² in relapsed or refractory follicular lymphoma, with more grade 3 or higher adverse events. The authors position epcoritamab plus R² as a new standard of care for second-line or subsequent treatment of follicular lymphoma.
Key findings
- Among 488 randomized participants (243 epcoritamab plus R²; 245 R²), overall response rate was 95% (95% CI 92–97) versus 79% (74–84; p<0·0001), and complete response rate was 83% (77–87) versus 50% (43–56; p<0·0001).
- Progression-free survival favored epcoritamab plus R² (HR 0·21 [95% CI 0·14–0·31], p<0·0001); median progression-free survival was not reached versus 11·7 months, and estimated 16-month progression-free survival was 85·5% versus 40·2%. Overall survival HR was 0·38 (95% CI 0·18–0·80, p=0·0039), with 16-month overall survival of 95·8% versus 88·8%.
- Grade 3 or higher adverse events occurred in 219 (90%) of 243 participants with epcoritamab plus R² versus 161 (68%) of 238 with R²; grade 3 or higher neutropenia occurred in 167 (69%) versus 100 (42%), and any-grade infections in 188 (77%) versus 125 (53%). Cytokine release syndrome with epcoritamab plus R² was low grade (grade 1 in 28 [21%] and grade 2 in seven [5%]) and all events resolved.
- Median follow-up was 14·8 months (IQR 11·4–19·0).
Methods
- Global, open-label, randomized phase 3 trial at 189 academic and non-academic centres in 30 countries; participants were adults aged 18 years or older with histologically confirmed CD20-positive classic follicular lymphoma stage II, III, or IV, relapsed or refractory after at least one previous anti-CD20-containing chemoimmunotherapy, ECOG performance status 0–2, at least one GELF criterion, and measurable disease per Lugano criteria.
- Participants were randomly allocated 1:1 to epcoritamab plus R² or R² for up to 12 cycles; epcoritamab was given subcutaneously weekly in cycles 1–3 and every 4 weeks in cycles 4–12, lenalidomide 20 mg orally once daily on days 1–21 during cycles 1–12, and rituximab 375 mg/m² intravenously weekly during cycle 1 and monthly during cycles 2–5.
- Dual primary endpoints were overall response rate and progression-free survival by independent review committee; the reported data are from a planned interim analysis after 78% of progression-free survival events had occurred. Overall response rate used a stratified Cochran-Mantel-Haenszel test; progression-free survival used Kaplan-Meier estimates and a stratified log-rank test, with hazard ratios from a stratified Cox proportional hazards model.
Limitations
- The paper states that the open-label design informs participants and investigators of treatment assignment, although independent review committee assessment was used for the dual primary endpoints; median follow-up was relatively short at 14·8 months; baseline characteristics were generally balanced except for a slightly higher proportion of participants aged 65 years or older, with FLIPI-2 scores 3–5, and with follicular lymphoma grade 3A in the R² group, which were not controlled by stratification factors.
- The paper states that the sample of participants with recent bendamustine use within 12 months was too small (seven participants) to provide meaningful conclusions.
- Evident from the text: the reported results are from an interim analysis after 78% of progression-free survival events, not the final analysis; overall survival did not meet its prespecified significance threshold, so the minimal residual disease endpoint was not tested; and patient-reported outcomes, complete response at end of treatment, and minimal residual disease negativity were not available at the time of writing because longer-term follow-up is ongoing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 13 Not valid · 7 Not checked · 125 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“However, only about half of participants had a complete response with R² in clinical trials. 5,8”
- Also stated in: § Introduction · plain
“However, only about half of participants had a complete response with R² in clinical trials.”
- Also stated in: § Evidence before this study · plain
“Although R2 offers a therapeutic option, only around half of treated patients have a complete response and most relapse, needing subsequent treatments.”
What the sources say
- Disputedcites [5] sourceExperimental — accuracy not yet measured
The Results > Efficacy section reports that 34% of participants receiving lenalidomide plus rituximab (R²) achieved a complete response—about one third, not about half. The 53% figure in the same passage is the overall response rate for the placebo-plus-rituximab group, not the R² complete-response rate. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [8] sourceExperimental — accuracy not yet measured
The Results (Efficacy; page unavailable) report a 52% complete-response rate with rituximab and lenalidomide, but this was a retrospective real-world cohort, not a clinical trial. The Discussion says its response rates were somewhat higher than those reported in a trial; it does not establish that about half of trial participants had a complete response. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Introduction · plain
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Lenalidomide enhances proliferation and activation of both T cells and natural killer cells. 17”
- Also stated in: § Evidence before this study · plain
“Lenalidomide enhances proliferation and activation of both T cells and natural killer cells.”
What the sources say
- Could not verifycites [17] sourceExperimental — accuracy not yet measured
The Anatomic Staging and Assessment of Response After Treatment passages discuss imaging and lymphoma response, not lenalidomide’s effects on immune cells. Searches for the quoted claim and for lenalidomide with T-cell and NK-cell activation or proliferation found no passage addressing it in our copy. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Evidence before this study · plain
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Unique among CD3 × CD20 T-cell engagers, preclinical studies have found minimal interference between epcoritamab and rituximab antitumour activity when combined, because each targets a different epitope on CD20.”
What the sources say
- Could not verifycites [18] sourceExperimental — accuracy not yet measured
The Methods and Results of the EPCORE NHL-1 C1 optimization abstract (page not provided) describe epcoritamab treatment in patients with relapsed or refractory follicular lymphoma, not preclinical combination studies. Searches for rituximab, CD20 epitopes, and interference with combined antitumour activity found no passage addressing the claim. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The chemotherapy-free combination of lenalidomide plus rituximab (R²) is an internationally accepted standard in individuals with relapsed or refractory follicular lymphoma who have received at least one previous line of therapy (second-line or subsequent treatment of follicular lymphoma).”
- Also stated in: § Summary · plain
“Lenalidomide and rituximab (R²) is an accepted standard of care in this population.”
What the sources say
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Methods and Results describe a multicenter trial of lenalidomide plus rituximab in previously treated patients, including those with follicular lymphoma; the Discussion reports a clinically meaningful efficacy advantage over rituximab alone. The paper does not establish that the combination was an internationally accepted standard of care. Its Introduction instead calls rituximab monotherapy a standard of care among several options. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [6] source
- Not checked — no full text of the sourcecites [7] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Summary · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“were higher for participants treated with epcoritamab plus R² due to overlapping toxicities in line with previous reports of T-cell engaging immunotherapies.”
What the sources say
- Partly supportedcites [14] sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes lenalidomide-induced neutropenia and unexpected toxicity with R² plus idelalisib, so it supports a general concern about toxicity in combinations. It does not report infection or neutropenia rates for epcoritamab plus R², or establish overlapping toxicities as the cause of higher rates in that group. (LLM, conf=0.84)
- Partly supportedcites [26] sourceExperimental — accuracy not yet measured
The Safety section reports neutropenia in 28.9% of patients receiving mosunetuzumab, and the Discussion says most serious infections occurred during its first four treatment cycles (page numbers unavailable). The paper does not study epcoritamab plus R² or establish that infections and neutropenia were higher with that combination because of overlapping toxicities. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [29] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
69 more claims · 3 with their cited sources checked
Create a free account to see all 151 claims and every source verdict.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 37
- The quote only partly states this claim. 4
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Discussion
“in our trial all participants had progressed after receiving an immunochemotherapy combination (ie, both anti-CD20 immunotherapy and alkylator-containing chemotherapy)”
§ Role of the funding source
“| Anti-CD20 antibody with chemotherapy | 239 (98%) | 240 (98%) |”
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00010 · Cited by 434
Flinn, I. W., van der Jagt, R., Kahl, B., Wood, P., Hawkins, T., MacDonald, D., Simpson, D., Kolibaba, K., Issa, S., Chang, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00605 · Cited by 311
Self-citationMechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma
Gribben, J. G., Fowler, N., & Morschhauser, F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5363 · Cited by 296
Self-citationBannerji, R., Arnason, J. E., Advani, R. H., Brown, J. R., Allan, J. N., Ansell, S. M., Barnes, J. A., O'Brien, S. M., Chávez, J. C., Duell, J., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00072-2 · Cited by 254
Engelberts, P. J., Hiemstra, I. H., de Jong, B., Schuurhuis, D. H., Meesters, J., Beltran Hernandez, I., Oostindie, S. C., Neijssen, J., van den Brink, E. N., Horbach, G. J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102625 · Cited by 172
Linton, K. M., Vitolo, U., Jurczak, W., Lugtenburg, P. J., Gyan, E., Sureda, A., Christensen, J. H., Hess, B., Tilly, H., Cordoba, R., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00166-2 · Cited by 171
Self-citationIacoboni, G., Navarro, V., Martín-López, A. Á., Rejeski, K., Kwon, M., Jalowiec, K. A., Amat, P., Reguera-Ortega, J. L., Gallur, L., Blumenberg, V., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01097 · Cited by 143
Cited by
Major, A., Ma, E., Masaquel, A. S., Tsang, M., Di, M., Kaur, S., Pophali, P. A., Werner, S., Bungay, R., Latrémouille-Viau, D., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag202 · Cited by 2
Giamaiou, P., Fioretzaki, R., Vassilakopoulos, T. P., & Dimou, M. (2026) · Medicina · doi:10.3390/medicina62061056 · Cited by 3
“CRS remained largely low grade, and its incidence decreased with optimized step-up dosing strategies [87].”
Self-citationSaleh, L. H., Ata, A. A., Alshaboul, F., Alani, A., & Askar, M. Z. (2026) · Current Research in Translational Medicine · doi:10.1016/j.retram.2026.103601 · Cited by 1
Caracciolo, D., Lombardo, M. R., Reitano, G., Napoli, C., Fiorillo, L., Callerame, C., Garritano, M., Bulotta, A., Munir, M., Pensabene, G., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70649 · Cited by 3
Vitolo, U., Falchi, L., Andersson, P., Nijland, M., Offner, F. C., Snauwaert, S., Christensen, J. H., Clausen, M. R., Fosså, A., Gómez‐Prieto, P., et al. (2026) · HemaSphere · doi:10.1002/hem3.70443 · Cited by 1
“16,17 21 Rituximab functions through NK ‐ cell – mediated antibody ‐ dependent cellular cytotoxicity of tumor cells, 22 and prior studies have shown that, despite both binding to CD20, neither epcoritamab nor rituximab negatively affects the tumor ‐ killing function of the other agent when combined…”
Self-citation
Metadata
- Authors
- Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., Jiménez-Ubieto, A., Gangatharan, S. A., Benjamini, O., Thieblemont, C., Tucci, A., Elinder-Camburn, A., Illes, A., Novak, J., Pavlovsky, M. A., McDonald, A., Yoon, D. H., Maruyama, D., Sunkersett, G., Mei, J. P., Mukherjee, N., Zhu, F., Alshreef, A., Favaro, E., Morschhauser, F., Tsirigotis, P., Pereira, J., Gonzalez de Villambrosia, S., Schmidt Filho, J., Avivi, I., Jurczak, W., Casasnovas, O., Miguel Bergua Burgues, J., Shen, J., Goldschmidt, N., Bouzani, M., Nagy, Z., Ysebaert, L., Houot, R., Tessoulin, B., Laurent Damaj, G., Vitolo, U., Manuel Sancho, J., Vanguru, V., Yeh, S.-P., Yan, X., Freeman, A., Larouche, J.-F., Modok, S., Patti, C., Sanchez Garcia, J., Roberto de Mattos, E., Walker, P., Ok Lee, J., Fukuhara, S., Mishima, Y., Jin, J., Qian, Z., Sterrett, R., Gurion, R., Rotter, N., Belada, D., Kopeckova, K., Trneny, M., Bouabdallah, K., LeBras, L., Waultier, A., Guidez, S., Feugier, P., Derenzini, E., Margiotta Casaluci, G., Sanchez Gonzalez, B., Lopez Jiménez, J., Gutierrez Gutierrez, N., Rodriguez, G., Carolina Caballero Gonzalez, A., de Jongh, E., Terpstra, W., Vermaat, J., Chen, T.-Y., Liu, H.-L., Ikezoe, T., Wu, H., Li, W., Jing, H., Kittai, A., Diefenbach, C., Hunter, B., Horowitz, N., Pichler, P., Mikala, G., Masszi, A., Drgona, L., Ngirabacu, M.-C., Janssens, A., Guieze, R., Durot, E., Haioun, C., Duell, J., Schalk, E., Tani, M., Carla Oliveira Ramos, A., Cordoba Mascunano, R., Grande Garcia, C., de la Fuente, A., Roost Clausen, M., Thomsen, T., Lagerlof, I., Nijhof, I., Johnson, R., Leao Cordeiro de, D., Bigni, R., Choong Lai, H., Issa, S., Shin, D.-Y., Chou, C.-W., Goto, H., Nakao, T., Li, C., Wei, X., Wei, X., Qian, W., Ma, S., Donthireddy, V., Diefenbach, C., Fesler, M., Hernandez-Ilizaliturri, F., Levy, M., Kumar, A., Yimer, H., Berz, D., Cabanillas, F., Koren Michowitz, M., Ozcan, M., Salim, O., Saydam, G., Turgut, M., Mehtap, O., Orhan Ayyildiz, M., Katodritou, E., Dimopoulos, M.-A., Rajnics, P., Van Hende, V., Roufosse, R., Vrelust, I., Morineau, N., Choquet, S., Bachy, E., Abraham, J., Kroschinsky, F., Herling, C., Ladetto, M., Scalzulli, P., Ferreri, A., Ferrero, S., Hohaus, S., Kallert, S., Johansson, B., Boersma, R., Libourel, E., Klerk, C., Wilson, M., Auer, R., Paneesha, S., Eyre, T., Lewis, D., Ayto, R., Osborne, W., Andrea Guanchiale, L., Chuah, H., Shetty, A., Cheah, C., Kilfoyle, A., Seog Kim, W., Shin, H.-J., Fujisaki, T., Kumode, T., Ishitsuka, K., Yuda, J., Yokoyama, H., Kato, K., Kitawaki, T., Kondo, T., Suehiro, Y., Ogawa, Y., Nakazawa, H., Tomita, A., Kamata, H., Lai, X., Shuang, Y., Gao, G., Liu, L., Yang, H., & Cen, X.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University Medical Center Groningen (NL)
- Sun Yat-sen University (CN)
- University of Manchester (GB)
- The Royal Melbourne Hospital (AU)
- Fudan University (CN)
- D’Or Institute for Research and Education (BR)
- National and Kapodistrian University of Athens (GR)
- Paracelsus Medical University (AT)
- Fiona Stanley Hospital (AU)
- Sheba Medical Center (IL)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- North Shore Hospital (NZ)
- Asan Medical Center (KR)
- The Cancer Institute Hospital (JP)
- AbbVie (United States) (US)
- Genmab (Denmark) (DK)
- Université de Lille (FR)
- Corresponding author
- Morschhauser, Franck
- ORCID
- Falchi, Lorenzo
- Nijland, Marcel
- Huang, Huiqiang
- Linton, Kim M
- Seymour, John F
- Tao, Rong
- Vassilakopoulos, Theodoros P
- Greil, Richard
- Gangatharan, Shane A
- Benjamini, Ohad
- Tucci, Alessandra
- Pavlovsky, Miguel A
- McDonald, Andrew
- Yoon, Dok Hyun
- Maruyama, Dai
- Zhu, Feng
- Alshreef, Abualbishr
- Favaro, Elena
- Morschhauser, Franck
- Tsirigotis, Panagiotis
- Pereira, Juliana
- Avivi, Irit
- Jurczak, Wojciech
- Casasnovas, Olivier
- Shen, Jianzhen
- Goldschmidt, Neta
- Nagy, Zsolt
- Houot, Roch
- Vitolo, Umberto
- Yeh, Su-Peng
- Yan, Xiaojing
- Freeman, Ashley
- Modok, Szabolcs
- Patti, Caterina
- Walker, Patricia
- Mishima, Yuko
- Jin, Jie
- Sterrett, Russell
- Gurion, Ronit
- Belada, David
- Bouabdallah, Kamal
- LeBras, Laure
- Feugier, Pierre
- Derenzini, Enrico
- de Jongh, Eva
- Terpstra, Wim
- Vermaat, Joost
- Liu, Hung-Lin
- Ikezoe, Takayuki
- Wu, Huijing
- Li, Wenyu
- Jing, Hongmei
- Kittai, Adam
- Horowitz, Netanel
- Janssens, Ann
- Duell, Johannes
- Schalk, Enrico
- Tani, Monica
- Johnson, Roderick
- Issa, Samar
- Shin, Dong-Yeop
- Chou, Cheng-Wei
- Goto, Hideki
- Li, Caixia
- Wei, Xiaolei
- Qian, Wenbin
- Ma, Shuo
- Berz, David
- Cabanillas, Fernando
- Salim, Ozan
- Turgut, Mehmet
- Katodritou, Eirini
- Dimopoulos, Meletios-Athanasios
- Morineau, Nadine
- Choquet, Sylvain
- Bachy, Emmanuel
- Abraham, Julie
- Kroschinsky, Frank
- Herling, Carmen
- Ladetto, Marco
- Scalzulli, Potito
- Ferrero, Simone
- Hohaus, Stefan
- Boersma, Rinske
- Wilson, Matthew
- Auer, Rebecca
- Ayto, Robert
- Osborne, Wendy
- Chuah, Hun
- Cheah, Chan
- Shin, Ho-Jin
- Kumode, Takahiro
- Ishitsuka, Kenji
- Yuda, Junichiro
- Yokoyama, Hisayuki
- Kondo, Tadakazu
- Suehiro, Youko
- Tomita, Akihiro
- Lai, Xun
- Gao, Guangxun
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2026-01
- Volume
- 407
- Issue
- 10524
- Pages
- 161-173
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4417091922
- Semantic Scholar
- b876405178d64fdd734cf4c98b60875a2de447a8
- Cited by
- 41
- References
- 22
- Citations by year
- 2026: 39
- FWCI
- 34.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- AbbVie
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- epcoritamab, lenalidomide, rituximab, relapsed/refractory follicular lymphoma, chemotherapy-free regimen, chemoimmunotherapy, overall response rate, progression-free survival, CAR T-cell therapy, B-cell lymphoma, treatment safety, interim analysis, fixed-duration treatment
- MeSH terms
- Rituximab, Antineoplastic Agents, Immunological, Lenalidomide, Progression-Free Survival, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Neoplasm Recurrence, Local, Treatment Outcome, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(25)02360-8
- The paper
- Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., Jiménez-Ubieto, A., Gangatharan, S. A., Benjamini, O., Thieblemont, C., Tucci, A., Elinder-Camburn, A., Illes, A., Novak, J., Pavlovsky, M. A., . . . Cen, X. (2026). Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(25)02360-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.